Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Vertex Pharmaceuticals IncorporatedUS flagNASDAQ Global Select
528.04
USD
+30.03
- -
134.02BMarket Cap

Valuation

Price vs. fair value · multiples
Price & Valuation BandSIGNATURE
Price against a fair-value channel (EPS × 12 / 15 / 23×)
+18.5% CAGROvervalued +109%
PriceFair value

Growth

Revenue · EPS · free cash flow
Revenue
Top line with YoY growth
+27.8% CAGR
RevenueYoY growth
EPS (Diluted)
Per-share earnings · loss years read red
EPSYoY growth
Free Cash Flow
Operating CF − capex, with FCF margin
Operating CFCapexFree cash flowFCF margin

Profitability

Margins & returns on capital
Gross Profit & Margin
Bars with margin trend line
+27.6% CAGR
Gross profitGross margin
Operating Income & Margin
Bars with margin trend line
Operating incomeOperating margin
Net Income & Margin
Loss years read red
Net incomeNet margin
ROIC · ROE · ROA
Returns on capital · ROE on right axis
ROICROEROA

Balance Sheet Health

Liquidity · leverage · share count
Cash vs. Debt
Liquidity & leverage, net-debt line
Cash & investmentsTotal debtNet debt
Shares Outstanding
Diluted share count · buybacks vs. dilution
+0.7% CAGR
Dividends & Payout Ratio
Dividend per share with payout overlay
No data available

Dividends & Payout Ratio isn’t reported for VRTX.

roic.ai · Fundamentals charts. Figures are not investment advice.